S
NRIX icon

SignatureFD’s Nurix Therapeutics NRIX Stock Holding History

SignatureFD’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.57K Hold
553
– – ﹤0.01% 2572
2025
Q4 		$10.5K Buy
553
+94
+20% +$1.35K ﹤0.01% 2408
2025
Q3 		$4.24K Sell
459
-66
-13% -$685 ﹤0.01% 2736
2025
Q2 		$5.98K Sell
525
-45
-8% -$486 ﹤0.01% 2541
2025
Q1 		$6.77K Hold
570
– – ﹤0.01% 2499
2024
Q4 		$10.7K Hold
570
– – ﹤0.01% 2336
2024
Q3 		$12.8K Hold
570
– – ﹤0.01% 2243
2024
Q2 		$11.9K Buy
570
+87
+18% +$1.35K ﹤0.01% 2197
2024
Q1 		$7.1K Sell
483
-197
-29% -$2.12K ﹤0.01% 2430
2023
Q4 		$7.02K Sell
680
-226
-25% -$1.55K ﹤0.01% 2402
2023
Q3 		$7.12K Sell
906
-108
-11% -$986 ﹤0.01% 2366
2023
Q2 		$10.1K Sell
1,014
-10
-1% -$102 ﹤0.01% 2229
2023
Q1 		$9.09K Buy
1,024
+1,014
+10,140% +$10.6K ﹤0.01% 2256
2022
Q4 		$110 Buy
+10
New +$121 ﹤0.01% 3228
2022
Q2 		– Sell
-48
Closed -$1K – 3273
2022
Q1 		$1K Buy
48
+42
+700% +$746 ﹤0.01% 3028
2021
Q4 		$0 Sell
6
-13
-68% -$394 ﹤0.01% 3214
2021
Q3 		$1K Sell
19
-7
-27% -$216 ﹤0.01% 2872
2021
Q2 		$1K Buy
+26
New +$763 ﹤0.01% 2784

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

SignatureFD's NRIX Position: Q1 2026 in Review

SignatureFD held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 553 shares worth $8.57K. The position accounts for ﹤0.01% of the portfolio, ranked #2572.

SignatureFD first reported a position in NRIX in Q2 2021 and has held it in 18 quarters since. The position peaked at $12.8K in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • SignatureFD held 553 shares of Nurix Therapeutics worth $8.57K as of Q1 2026.
  • SignatureFD left its Nurix Therapeutics share count unchanged in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #2572 holding.
  • SignatureFD first reported a position in Nurix Therapeutics in Q2 2021 and has held it in 18 quarters since.
  • SignatureFD's Nurix Therapeutics position peaked at $12.8K in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.